BlueCrest Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

BlueCrest Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-45,000	Closed	-$2.44M	–	137
2024 Q1	$2.44M	Sell	45,000 -48,200	-52%	-$2.46M	0.12%	106
2023 Q4	$4.78M	Buy	93,200 +56,400	+153%	+$2.96M	0.18%	104
2023 Q3	$2.14M	Buy	+36,800	New	+$2.25M	0.09%	133

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlueCrest Capital Management's BMY Position: Q2 2024 in Review

BlueCrest Capital Management sold out of Bristol-Myers Squibb (BMY) in Q2 2024, closing a stake of 6,364 shares — an estimated $345K sold.

BlueCrest Capital Management first reported a position in BMY in Q4 2015 and held it in 10 quarters. The position peaked at $3.03M in Q4 2023. 2,148 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

BlueCrest Capital Management reported no remaining Bristol-Myers Squibb position as of Q2 2024 after selling out during the quarter.
BlueCrest Capital Management sold 6,364 Bristol-Myers Squibb shares in Q2 2024, an estimated $345K.
BlueCrest Capital Management first reported a position in Bristol-Myers Squibb in Q4 2015 and held it in 10 quarters.
BlueCrest Capital Management's Bristol-Myers Squibb position peaked at $3.03M in Q4 2023.
2,148 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on BlueCrest Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.